ANRO Alto Neuroscience, Inc.

NYSE
$27.12

Alto Neuroscience, Inc. (ANRO) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.54 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.8% since its last earnings release on November 10, 2026.

Alto Neuroscience Beat Consensus Estimates
Tuesday, November 10, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 9
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.54)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $29.91

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Alto Neuroscience, Inc.

Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company. Its clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia and other mental health conditions. Alto Neuroscience Inc. is based in LOS ALTOS, Calif.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.